Rocket Doctor Grants RSUs and Stock Options

Rhea-AI Summary

Rocket Doctor AI (OTC:AIRDF) granted an aggregate 831,356 restricted share units (RSUs) and 20,964 stock options to consultants and employees on Nov 7, 2025.

The Options are exercisable for one common share at an exercise price of C$0.82 per share for a three‑year term and are subject to vesting provisions and plan terms.

• RSU terms: 325,000 RSUs expire in two years; 506,356 RSUs expire in three years.
• Vesting: 203,000 RSUs vest immediately; 628,356 RSUs are subject to vesting provisions.
• All grants are subject to the company equity plans and applicable securities law hold periods.

Vancouver, BC, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that it has granted an aggregate 831,356 restricted share units (“RSUs”) and 20,964 stock options (“Options”) to consultants and employees of the Company and its subsidiary, Rocket Doctor Inc.

The Options are each exercisable for one common share of the Company at an exercise price of C$0.82 per share for a period of three years from the grant date and subject to vesting provisions. 325,000 RSUs are valid for a term of two years and 506,356 RSUs are valid for a term of three years. 203,000 RSUs vest immediately and 628,356 are subject to vesting provisions.  All Options and RSUs are subject to the terms of the Company’s equity plans and applicable securities law hold periods.

About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc’s products and services, contact:

www.rocketdoctor.ai  or email: info@rocketdoctor.ai

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai

Dr. Bill Cherniak, CEO, Rocket Doctor Inc.
bill@rocketdoctor.io


For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321

Cautionary Statements

This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

Holly Iervella

FAQ

What equity awards did Rocket Doctor AI (AIRDF) grant on November 7, 2025?

The company granted 831,356 RSUs and 20,964 stock options to consultants and employees.

What is the exercise price and term for the AIRDF stock options granted Nov 7, 2025?

Each option is exercisable for one share at an exercise price of C$0.82 and expires three years from the grant date.

How many Rocket Doctor AI (AIRDF) RSUs vested immediately in the November 7, 2025 grant?

203,000 RSUs vest immediately; the remaining RSUs are subject to vesting provisions.

What are the expiry terms for the RSUs in the AIRDF Nov 7, 2025 grant?

Of the RSUs, 325,000 are valid for two years and 506,356 are valid for three years.

Are AIRDF’s Nov 7, 2025 grants subject to holding periods and equity plan rules?

Yes, all Options and RSUs are subject to the company’s equity plans and applicable securities law hold periods.